Cti Biopharma Corp (CTIC): James A Bianco , President and CEO of Cti Biopharma Corp sold 10,000 shares on May 27, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $0.45 per share for a total value of $4,471.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 29, 2016, James A Bianco (President and CEO) sold 10,000 shares at $0.52 per share price.On Mar 4, 2016, Matthew Plunkett (EVP, Chief Business Officer) sold 10,000 shares at $0.59 per share price.Also, On Feb 26, 2016, Jack W Singer (EVP, Chief Scientific Officer) sold 15,000 shares at $0.63 per share price.On Nov 20, 2015, Louis A Bianco (EVP, Finance & Administration) sold 15,000 shares at $1.13 per share price.
CTI BioPharma Corp: On Wednesday, May 25, 2016 heightened volatility was witnessed in CTI BioPharma Corp which led to swings in the share price. The shares opened for trading at $0.4517 and hit $0.4639 on the upside , eventually ending the session at $0.4563, with a gain of 1.40% or 0.0063 points. The heightened volatility saw the trading volume jump to 6,09,328 shares. The 52-week high of the share price is $2.46 and the company has a market cap of $129 M . The 52-week low of the share price is at $0.2514.
CTI BioPharma Corp. (CTI) formerly Cell Therapeutics Inc. is a biopharmaceutical company focused on the acquisition development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone) or PIXUVRI in the European Union for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.